Welcome to the e-CCO Library!

P609: A treat-to-target approach via a virtual clinic amongst inflammatory bowel disease patients with secondary loss of response to anti-TNF therapy improves clinical outcomes
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Little R., Taylor K., Friedman A., Headon B., Gibson P., Sparrow M., Ward M.

Created: Wednesday, 20 February 2019, 10:36 AM
P609: Handsewn anastomosis after ileo-colic resection for Crohn’s disease: a lost art?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Gouvea Monteiro de Camargo1, S. Brandstetter1, A. Aiello2, L. Stocchi1, T. Hull1, I. Lavery1, J. M. Church1, S. R. Steele1, M. Valente1, S. Holubar*1

Created: Friday, 22 February 2019, 9:41 AM
P609: Impact of accessibility of medical care and socioeconomic class on outcomes of IBD – a nationwide population study
Year: 2021
Source: ECCO'21 Virtual
Authors: Ledder, O.(1);Harel, S.(1);Orlanski-Meyer, E.(1);Yogev, D.(1);Loewenberg Weisband, Y.(2);Greenfeld, S.(3);Kariv, R.(3);Lederman, N.(4);Matz, E.(5);Schwartz, D.(6);Focht, G.(1);Dotan, I.(7);Turner, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P609: Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Colombel, J.F.(1)*;Rubin, D.T.(2);Vermeire, S.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Dignass, A.(5);Regueiro, R.(6);
Created: Friday, 14 July 2023, 11:05 AM
P609: Significant variations in practice in managing mild-Crohn’s disease: results from the 2021 Y-ECCO-ClinCom survey
Year: 2022
Source: ECCO'22
Authors: Dart, R.(1,2);Irving, P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P609: Uncertain usefulness of infliximab trough levels for therapeutic decision-making in inflammatory bowel disease patients on infliximab maintenance therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Cañete1,2*, T. Lobatón2, E. Cabré2,3, M. Mañosa2,3, A. Teniente4, A. Clos2, P. Torres2, G. Valldosera2, E. Martínez-Cáceres4, E. Domènech2,3

Created: Thursday, 21 February 2019, 9:14 AM
P610 Optimising biological therapy in inflammatory bowel disease patients: the role of a virtual biological clinic
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. REES, C. Maher, J. Jones, J. Slater, B. Bates, D. Rattehalli, S. De Silva

Created: Thursday, 30 January 2020, 10:12 AM
P610: Efficacy and safety of GLPG1205, a GPR84 antagonist, in ulcerative colitis: multi-centre proof-of-concept study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vermeire S.*1, Reinisch W.2,3, Wasko-Czopnik D.4, Van Kaem T.5, Desrivot J.6, Vanhoutte F.5, Beetens J.5

Created: Wednesday, 20 February 2019, 10:36 AM
P610: Fear of COVID-19 among persons with Inflammatory Bowel Disease according to employment status, educational background and residential setting, as compared to persons with other gastrointestinal conditions
Year: 2021
Source: ECCO'21 Virtual
Authors: Lo, B.Z.S.(1);Mokrowiecka, A.(2);Mikocka-Walus, A.(3);Bernstein, C.N.(4,5);Trindade, I.A.(6);Burisch, J.(1);Barreiro-de Acosta, M.(7);Ferreira, N.(8);Gearry, R.B.(9);Knowles, S.R.(10);
Created: Wednesday, 2 June 2021, 4:12 PM
P610: Penetration, short- and long-term efficacy of anti-TNF-α therapy for ulcerative colitis between 2010–2016 in Hungary
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Molnár*1, F. Nagy1, Z. Szepes1, K. Farkas1, R. Bor1, A. Bálint1, Á. Milassin1, A. Fábián1, M. Rutka1, K. Szántó1

Created: Friday, 22 February 2019, 9:41 AM
P610: Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Irving, P.M.(1);Hur, P.(2)*;Gautam, R.(3);Guo, X.(4);Vermeire, S.(5);
Created: Friday, 14 July 2023, 11:05 AM
P610: Risk of active Hepatitis B and C infections in the Phases 2 and 3 clinical trial programmes for ustekinumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Gish1, P. Ramachandran2, W. Xu2, S. Sloan2*

Created: Thursday, 21 February 2019, 9:14 AM
P610: Safety of COVID-19 vaccine in patients with Inflammatory Bowel Disease: preliminary data of a national study (ESCAPE-IBD)
Year: 2022
Source: ECCO'22
Authors: Todeschini, A.(1);Macaluso, F.S.(2);Contaldo, A.(3);Mannino, M.(2);Orlando, A.(2);Principi, M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P611 Provision of care for pregnant women with IBD in the UK - the current landscape
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Moore1, S. Wolloff1, T. Glanville2, C.P. Selinger1

Created: Thursday, 30 January 2020, 10:12 AM
P611: A real-world assessment of golimumab effect on quality of life, healthcare resource utilisation and work productivity in patients with ulcerative colitis in Greece: interim results from the GO-LIFE study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Mantzaris*1, A. Gatopoulou2, D. Christodoulou3, K. Katsanos3, I. Mouzas4, M. Tzouvala5, G. Paspatis6, K. Thomopoulos7, S. Michopoulos8, G. Koujlakis9, I. Pachiadakis10, K. Triantafyllou11, P. Karatzas12, D. Moschovis13, G. Theocharis7, M. Tampaki14

Created: Friday, 22 February 2019, 9:41 AM
P611: COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS. ANTI-TNFs IN CROHN'S DISEASE BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Muñoz Nuñez, J.F.(1)*;Rodríguez, C.(2);Gisbert, J.P.(3);Bernardo, S.(4);Aparicio, J.(5);Tagarro, I.(5);Casellas, F.(6);
Created: Friday, 14 July 2023, 11:05 AM
P611: Incidence, clinical presentation, and severity of SARS-CoV-2 infection in IBD patients in the second and the third wave of infection
Year: 2021
Source: ECCO'21 Virtual
Authors: Algaba Garcia, A.(1);Guerra, I.(1);Castro, S.(2);Jiménez, L.(1);Garza, D.(1);Aller, M.D.M.(1);Granja, A.(1);Guardiola, A.(1);Bellart, M.(2);Pizarro, N.(2);Bermejo, F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P611: Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre study
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Viola1*, D. Pugliese2, S. Renna3, F. Furfaro4, F. Caprioli5, R. D'Inca'6, F. Bossa7, G. Costantino1, M. Fantini8, G. Fiorino4, A. Armuzzi2, A. Orlando3, W. Fries1

Created: Thursday, 21 February 2019, 9:14 AM
P611: Relapse risk and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bots S., Kuin S., Ponsioen C., van den Brink G., Löwenberg M., D'Haens G.

Created: Wednesday, 20 February 2019, 10:36 AM
P611: Serological biomarkers of type VI and XXII collagen formation predict and monitor infliximab treatment response in patients with Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Sorokina Alexdóttir, M.(1);Bourgonje, A.R.(2);Karsdal, M.A.(1);Bay-Jensen, A.C.(1);Pehrsson, M.(1);Loveikyte, R.(2);van Dullemen, H.M.(2);Visschedijk, M.C.(2);A. M. Festen, E.(2); Weersma, R.K.(2);Faber, K.N.(2);Dijkstra, G.(2);Mortensen, J.H.(1);
Created: Friday, 11 February 2022, 3:56 PM